Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
about
IL-6 Contributes to the Defective Osteogenesis of Bone Marrow Stromal Cells from the Vertebral Body of the Glucocorticoid-Induced Osteoporotic Mouse.Sarcopenia and Sarcopenic Obesity in Patients Undergoing Orthopedic Surgery.Sarcopenia and OsteoporosisMuscle-bone and fat-bone interactions in regulating bone mass: do PTH and PTHrP play any role?Implications of exercise-induced adipo-myokines in bone metabolism.Novel bone metabolism-associated hormones: the importance of the pre-analytical phase for understanding their physiological roles.Pathophysiology of Bone Fragility in Patients with Diabetes.Differential impact of the bisphosphonate alendronate on undifferentiated and terminally differentiated human myogenic cells.Soluble Inflammatory Markers and Risk of Incident Fractures in Older Adults: The Cardiovascular Health Study.Bisphosphonates prevent age-related weight loss in Japanese postmenopausal women.Preventing muscle wasting by osteoporosis drug alendronate in vitro and in myopathy models via sirtuin-3 down-regulation.Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal.
P2860
Q36003384-0F9CF9F4-4107-49FF-8991-F30CDC08CE15Q36909879-CBB2D92F-80B9-4F2F-A974-EEEAB19CE8D2Q37150045-500378AB-3D0B-49F4-9A98-2677DBF1DB0AQ38209810-18B438AD-D3F5-48DA-9710-5818075F329BQ38683297-085ABC28-585A-4697-9D4D-E96201B59D99Q38970563-EFF2073B-C4CC-4EE7-9D33-2829ECA29C13Q39127683-8FF2C79A-55D2-42AF-A904-7633D0A32B94Q43694442-69ECF939-B077-4EAF-B7FA-35AB763D438DQ46056287-BDB60975-E97E-46D9-8008-1F2D155F02EAQ47174018-7C5760C4-8E98-48C8-89EE-568D676E93C0Q51735670-2A943A45-52F8-4C1F-BDB5-7B38A2557047Q55518613-A0C726F8-272F-45FF-9D74-1E7F50F56E06
P2860
Concomitant increase in muscle strength and bone mineral density with decreasing IL-6 levels after combination therapy with alendronate and calcitriol in postmenopausal women.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Concomitant increase in muscle ...... triol in postmenopausal women.
@en
Concomitant increase in muscle ...... triol in postmenopausal women.
@nl
type
label
Concomitant increase in muscle ...... triol in postmenopausal women.
@en
Concomitant increase in muscle ...... triol in postmenopausal women.
@nl
prefLabel
Concomitant increase in muscle ...... triol in postmenopausal women.
@en
Concomitant increase in muscle ...... triol in postmenopausal women.
@nl
P2093
P50
P1433
P1476
Concomitant increase in muscle ...... itriol in postmenopausal women
@en
P2093
Hoon Suk Park
Joo Hyun Park
Ki Hyun Park
P304
P356
10.1097/GME.0B013E31827CABCA
P407
P577
2013-07-01T00:00:00Z